

SUPPLEMENTARY.

Table S4. Main characteristics of the selected articles for the evaluation of the use of melatonergic antidepressants in comorbid depression and Parkinson's disease

Author, year	Sample characteristics	Affective disorder	Affective disorder assessment criteria	Details of medication treatment	Concomitant therapy	Duration of follow-up	Primary outcomes	Secondary outcomes	Adverse events	Number of dropouts
Avila, Cardona, et al., 2015	n=24, 50% men, mean age 75.2 ±8.3 years.	Depression	DSM-IV	Agomelatine 26.56 ± 5.61 mg (range 25–50 mg) at week 12 and 25.00 ±10.43 mg (range 25–50 mg) at week 24	Antiparkinsonian medication remained unchanged for 4 weeks before and throughout the study.	6 months	↓HAM-D (p <0.0005)	↓UPDRS part III, p <0.0005 ↓SCOPA-SNS, p <0.005 ↓SCOPA-S LM, p <0.0005 ↓SCOPA-S DS, p <0.0005 ↓PDSS, p <0.0005 ↓S-E p <0.0005	Constipation, nausea, rash, headache and dizziness	3
Fedorova, Kuluva, et al., 2015	n=35 (of which 15 were a control group without antidepressants), no data, mean age 65.5±12.5 years.	Affective disorders	NINDS	Agomelatine (Valdoxan) 25 mg	Antiparkinsonian treatment.	6 weeks	↓HAM-D (p <0.05)	↓PSQI, p <0.05 ↓Epworth Sleepiness Scale, p <0.05 ↓PDQ-39, p <0.05 ↓TMAS, p <0.05 ↓LARS, p <0.05 ↓SHAPS, p <0.05	Mild transient headache	0
Golubev, Pilipovich, et al., 2014	n=40, 25% men, mean age 63±1.9 years	Depression	DSM-IV	Agomelatine (Valdoxan) 25 mg	No data	4 weeks	↓HAM-D	↓total UPDRS score (p <0.05), ↓UPDRS, part I (p <0.05) ↑LSEQ, ↓ISI, ↑mood by VAS (p <0.05)	No data	0
Gustov, et al., 2015	n=18, 44.4% men, mean age 65.0±6.5 years	Depressive disorder	No data	Agomelatine (Valdoxan) 25 mg	Antiparkinsonian therapy (levodopa, dopamine agonists, rasagiline).	2 months	↓HADS depression (p=0.001) ↓BDI (p=0.0002)	↓STAI (p=0.0048) ↓Dyssomnia (p=0.002)	No data	0

Note: DSM-IV — Diagnostic and Statistical Manual of mental disorders, 4th edition; NINDS — recommendations of the National Institute of Neurological Disorders and Stroke; HAM-D — Hamilton Depression Rating Scale; TMAS — Taylor Manifest Anxiety Scale; SHAPS — Snaith–Hamilton Pleasure Scale; LARS — Lille Apathy Rating Scale; PSQI — Pittsburgh Sleep Quality Index; PDQ-39 — Parkinson's Disease Quality of life questionnaire; UPDRS — Unified Parkinson's Disease Rating Scale; S-E — Schwab and England ADL (Activities of Daily Living) scale; PDSS — Parkinson's Disease Sleep Scale; SCOPA-SNS — Scales for Outcomes in Parkinson's Disease — Nighttime Sleep; SCOPA-S LM — Scales for Outcomes in Parkinson's Disease-Nighttime Sleep Last Month; SCOPA-SDS — Scales for Outcomes in Parkinson's Disease-Daytime Sleepiness; ISI — Insomnia Severity Index; LSEQ — Leeds Sleep Evaluation Questionnaire; BDI — Beck Depression Inventory; STAI — Spielberger State-Trait Anxiety Inventory; VAS — Visual Analogue Scale; ↓ — decrease in indicators; ↑ — increase in indicators.